Furthermore, Akt activates Mdm2 [27], therefore Mdm2 antagonists, for example, Milademetan [100] and AMG-232 (Navtemadlin) [112] in the case of AML patients expressing phosphorylated Akt may be especially reasonable choices. The gene discussed is AKT1; the disease is acute myeloid leukemia.